<DOC>
	<DOCNO>NCT02288273</DOCNO>
	<brief_summary>A Randomized , Double-blind , Parallel-group Study Evaluate Effect Bydureon Compared Placebo 24-hour Glucose Control Metformin-treated Patients Type 2 Diabetes .</brief_summary>
	<brief_title>Study Evaluate Effect BYDUREON 24-hour Glucose Control Metformin Treated Patients With Type 2 Diabetes .</brief_title>
	<detailed_description>A Randomized , Double-blind , Parallel-group Study Evaluate Effect Bydureon Compared Placebo 24-hour Glucose Control 110 Metformin-treated Patients Type 2 Diabetes</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes mellitus ( T2DM ) treat stable dose metformin &gt; = 1500mg/day monotherapy least 8 week Hemoglobin A1c ( HbA1c ) 7 % 10 % screen Body mass index ( BMI ) &lt; = 45 kg/m2 History take antihyperglycemic therapy metformin metformin extend release ( XR ) 8 week prior screen History take dipeptidyl peptidase4 ( DPP4 ) inhibitor pramlintide 12 week prior screen History potent , inhale intrapulmonary steroid 3 month prior screen study History prescription counter weight loss medication 3 month prior screen Previous exposure exenatide glucagonlike peptide1 ( GLP1 ) receptor agonist 6 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>